The document discusses the Biopharmaceutics Classification System (BCS), which is a framework developed by the FDA to classify drugs based on their aqueous solubility and intestinal permeability. The BCS aims to improve drug development and review processes by identifying when clinical bioequivalence tests are not necessary. It classifies drugs as Class I (high solubility, high permeability), Class II (low solubility, high permeability), Class III (high solubility, low permeability) or Class IV (low solubility, low permeability) based on their solubility and permeability parameters. The classification can help determine if in vitro dissolution tests alone can demonstrate bioequivalence or if in vivo testing is still required.